Cullinan Therapeutics Inc Dossier - Source-backed chat

Cullinan Therapeutics Inc

CGEMNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.35

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $14.53Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $893M

Enterprise Value $816.7M

Shares Outstanding 61.5M diluted

Next Earnings Date31 Dec 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Cullinan Therapeutics is a highly promising clinical-stage biopharmaceutical company that has successfully pivoted its core focus toward T-cell engagers (TCEs) for autoimmune diseases and oncology. The company's lead asset, CLN-978 (a subcutaneous CD19xCD3 bispecific TCE), demonstrated exceptional initial Phase 1 data at the EULAR 2026 Congress, showing deep B-cell depletion and clinical remissions in refractory SLE and RA patients with a highly manageable safety profile. Backed by a robust cash position of $393.3 million (providing a runway into 2029) and a near-term commercial catalyst in zipalertinib (PDUFA date of February 27, 2027, in partnership with Taiho), Cullinan offers a highly asymmetric risk-reward profile for biotech investors.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets11 analysts · as of 18 Aug 2026

Low · most bearish analyst$23.00

Mean target$32.36

High · most bullish analyst$42.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

Safety concerns emerge for CLN-978 in larger patient cohorts, such as an increased frequency of Grade 3 CRS or neurotoxicity, limiting its outpatient viability. Zipalertinib faces regulatory delays or a complete response letter (CRL) from the FDA, postponing commercialization. High R&D burn rates accelerate cash consumption, shortening the runway.

Base CaseCentral scenario

CLN-978 continues to demonstrate robust, deep B-cell depletion in peripheral blood and tissues across expanded multi-dose cohorts in SLE and RA, maintaining a safety profile suitable for outpatient subcutaneous administration. Zipalertinib receives FDA approval by its PDUFA date of February 27, 2027, triggering a $30 million milestone payment and establishing a steady 50/50 profit-share stream in the U.S. CLN-049 advances smoothly toward a pivotal trial in AML.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong clinical proof-of-concept for CLN-978 presented at EULAR 2026, showing 71% of SLE patients achieved a clinical response and 5 achieved DORIS remission.
Subcutaneous administration of CLN-978 allows for convenient outpatient, community-based care, offering a massive commercial advantage over intravenous CAR-T therapies.
Robust balance sheet with $393.3 million in cash and investments as of March 31, 2026, securing an operational runway into 2029 and eliminating near-term dilution risk.
De-risked oncology portfolio with zipalertinib NDA accepted by the FDA (PDUFA date Feb 27, 2027), eligible for up to $130 million in regulatory milestones and a 50/50 U.S. profit share.

Key Investment Risks

Clinical-stage execution risk, particularly regarding safety profiles (e.g., managing CRS at higher doses of CLN-978).
Heavy reliance on partner Taiho Oncology for the regulatory approval and commercial execution of zipalertinib.
Intense competition in the autoimmune B-cell depletion space from both established CAR-T therapies and emerging bispecific T-cell engagers.

Thesis Invalidation Triggers

Occurrence of severe, systemic safety issues (such as Grade 3+ ICANS or widespread Grade 3+ CRS) in the 10-30 µg dose cohorts of CLN-978.
FDA rejection or significant approval delay of zipalertinib on or after the February 27, 2027 PDUFA date.
Failure of CLN-049 to establish a recommended Phase 2 dose (RP2D) due to insufficient efficacy or unacceptable toxicity in AML patients.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.